{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', 'investigational subject administered a medicinal product and which does not necessarily have a', 'causal relationship with this treatment. Since bleeding episodes are recorded as an efficacy', 'assessment of fitusiran, these will not be treated as AEs unless they meet any of the SAE criteria', 'listed in Section 7.5.6.1.', 'Serious Adverse Event', 'An SAE is any untoward medical occurrence that at any dose:', 'Results in death', 'Is life-threatening (an event which places the patient at immediate risk of death from', 'the event as it occurred. It does not include an event that had it occurred in a more', 'severe form might have caused death)', 'Requires in-patient hospitalization or prolongation of existing hospitalization', 'Results in persistent or significant disability or incapacity', 'Is a congenital anomaly or birth defect', 'Is an important medical event that may not be immediately life-threatening or result', 'in death or hospitalization but may jeopardize the patient and may require', 'intervention to prevent one of the other outcomes listed in the definition above (eg,', 'events include allergic bronchospasm requiring intensive treatment in an emergency', 'room or at home, blood dyscrasias, convulsions, or the development of drug', 'dependency or abuse).', 'Bleeding episodes will be recorded for efficacy assessment of fitusiran and will not', 'be treated as AEs unless they meet any of the above criteria for SAEs.', 'Adverse Events of Special Interest', 'The following events are considered to be AEs of special interest (AESI):', 'ALT or AST elevations >3x ULN', 'Suspected or confirmed thrombosis', 'Severe or serious ISRs, ISRs that are associated with a recall phenomenon (reaction at', 'the site of a prior injection with subsequent injections) or, those that lead to', 'temporary dose interruption or permanent discontinuation of fitusiran', 'Systemic injection associated reactions (IARs), defined as hypersensitivity reactions', 'which are related or possibly related to IMP.', 'Property of the Sanofi Group - strictly confidential', '61']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', 'Adverse Event Severity', 'Adverse events are to be graded according to the categories detailed below:', 'Mild:', 'Mild; asymptomatic or mild symptoms; clinical or diagnostic observations', 'only; intervention not indicated', 'Moderate:', 'Moderate; minimal, local or noninvasive intervention indicated; limiting age', 'appropriate instrumental activities of daily living (eg, preparing meals,', 'shopping for groceries or clothes, using the telephone, managing money)', 'Severe:', 'Severe or medically significant but not immediately life-threatening;', 'hospitalization or prolongation of hospitalization indicated; disabling; limiting', 'self-care activities of daily living (ie, bathing, dressing and undressing, feeding', 'self, using the toilet, taking medications, and not bedridden); OR life-', 'threatening consequences; urgent intervention indicated; OR death related to', 'an AE', 'Changes in severity should be documented in the medical record to allow assessment of the', 'duration of the event at each level of severity. Adverse events characterized as intermittent', 'require documentation of the start and stop of each incidence. When changes in the severity of', 'an AE occur more frequently than once a day, the maximum severity for the experience that day', 'should be noted. If the severity category changes over a number of days, then those changes', 'should be recorded separately (with distinct onset dates).', 'AE severity and seriousness are assessed independently. \"Severity\\' characterizes the intensity of', 'an AE. \"Serious\\' is a regulatory definition and serves as a guide to the Sponsor for defining', 'regulatory reporting obligations (see definition for SAE).', 'Relationship of the Adverse Event to Study Treatment', 'The relationship of each AE to study treatment should be evaluated by the Investigator using the', 'following criteria:', 'Definitely related:', 'A clinical event, including laboratory test abnormality, occurring in a plausible', 'time relationship to the medication administration, and which cannot be', 'explained by concurrent disease or other drugs or chemicals. The response to', 'withdrawal of the drug should be clinically plausible.', 'Possibly related:', 'A clinical event, including laboratory test abnormality, with a reasonable time', 'sequence to the medication administration, but which could also be explained', 'by concurrent disease or other drugs or chemicals. Information on the drug', 'withdrawal may be lacking or unclear.', 'Unlikely related:', 'A clinical event, including laboratory test abnormality, with little or no', 'temporal relationship to medication administration, and which other drugs,', 'chemicals, or underlying disease provide plausible explanations.', 'Not related:', 'A clinical event, including laboratory test abnormality that has no temporal', 'relationship to the medication or has more likely alternative etiology.', 'Property of the Sanofi Group - strictly confidential', '62']\n\n###\n\n", "completion": "END"}